In the treatment of cardiovascular disease (CVD), national
|
|
- Rudolf Brooks
- 6 years ago
- Views:
Transcription
1 n report n Beyond LDL Cholesterol: The Role of Elevted Triglycerides nd Low HDL Cholesterol in Residul CVD Risk Remining After Sttin Therpy Peter Algon Jr, MD, FACC In the tretment of crdiovsculr disese (CVD), ntionl guidelines nd mny helthcre professionls focus on lowdensity lipoprotein (LDL) cholesterol. However, rther thn viewing LDL cholesterol level s therpeutic end point, helthcre professionls should consider modifiction of therothrombosis nd prevention of CVD events s the gol of ny lipid-ltering therpy or preventive strtegy. Tretments for mture CVD, including mechnicl revsculriztion, should be considered pllitive therpies tht help tret n episode in wht is chronic disese process. Mny ptients who undergo these interventions re going to hve dditionl or repet procedures relted to the progression of coronry rtery disese (CAD) or peripherl rteril disese. Consequently, it is importnt to recognize tht for these ptients to decrese their risk of recurrent events, they need to utilize every ggressive, preventive tretment strtegy vilble. This my include ddressing severl non-ldl cholesterol lipid prmeters. 1 Approximtely 28% of dults in the United Sttes hve high LDL cholesterol nd third or more hve high triglycerides (TGs) nd/ or low high-density lipoprotein (HDL) cholesterol. Almost 5% of dults hve t lest 1 lipid bnormlity. 2 One of the most effective clsses of medictions for preventing crdiovsculr events is hydroxymethylglutryl-coenzyme A reductse inhibitors, or sttins. However, exmintion of sttin clinicl tril dt revels tht significnt number of ptients being treted continue to experience crdiovsculr events. In the 4S (Scndinvin Simvsttin Survivl Study) tril, which studied ptients with very high LDL cholesterol levels nd known coronry hert disese (CHD), significnt risk reduction ws observed with sttin tretment. Although the reltive risk of mjor crdiovsculr event decresed by pproximtely one third, the results from 4S lso indicte tht over the study s durtion lmost 2% of sttin-treted ptients hd crdiovsculr event. 3 Indeed, dt collected from severl mjor sttin trils hve consistently reveled the existence of significnt residul crdiovsculr risk even fter lrge reductions of LDL cholesterol (Figure 1). 3-8 Additionl trils hve included high-risk ptients with CHD or dibetes mellitus who were treted with intensive LDLlowering sttin therpy. In the PROVE IT-TIMI 22 (Prvsttin or Atorvsttin Evlution nd Infection Therpy Thrombolysis in Mnged Cre & Helthcre Communictions, LLC Abstrct Mnged cre inititives to reduce crdiovsculr disese (CVD) risk hve, to dte, focused lmost exclusively on sttins, which re primrily low-density lipoprotein cholesterol lowering gents nd hve limited effects on triglycerides nd highdensity lipoprotein (HDL) cholesterol t commonly used doses. Significnt residul CVD risk (ie, risk of recurrent CVD events) remins fter tretment with sttins nd my stem, t lest prtilly, from low HDL cholesterol nd/or elevted triglycerides. Consequently, ntionl tretment guidelines suggest tht combintion therpy my be necessry to ddress multiple lipid trgets nd dding nicin or fibrte to sttin is strtegy to be considered. Recent clinicl tril evidence hs demonstrted the efficcy of nicin/sttin nd fenofibric cid/sttin combintion therpies in treting multiple lipid bnormlities. (Am J Mng Cre. 29;15:S65-S73) For uthor informtion nd disclosures, see end of text. VOL. 15, No. 3 n The Americn Journl of Mnged Cre n S65
2 Report n Figure 1. Residul CVD Risk After Sttin Therpy Ptients Experiencing Mjor CHD Events, % 35% % 28% 29% 26% 25% In mjor sttin trils, significnt reductions in CHD events occur with sttins compred with plcebo. However, substntil percentge of mjor CHD events still occurs in the sttin-treted groups. 3-8 AFCAPS/TexCAPS indictes Air Force/Texs Coronry Atherosclerosis Prevention Study; CARE, Cholesterol nd Recurrent Events; CHD, coronry hert disese; CVD, crdiovsculr disese; 4S, Scndinvin Simvsttin Survivl Study; HPS, Hert Protection Study; LDL, low-density lipoprotein; LIPID, Long-Term Intervention with Prvsttin in Ischemic Disese; WOSCOPS, West of Scotlnd Coronry Prevention Study. Myocrdil Infrction 22) study, 4162 ptients with cute coronry syndromes (ACS) were treted with either prvsttin 4 mg or torvsttin 8 mg. 9 Clinicl events were further reduced in the high-dose torvsttin group compred with the prvsttin group; however, during the 2-yer tril, 22.4% of the individuls treted with high-dose torvsttin still suffered mjor CVD event despite chieving men LDL cholesterol levels of 62 mg/dl. 9 Similr results were observed in the IDEAL (Incrementl Decrese in End Points Through Aggressive Lipid Lowering) nd TNT (Treting to New Trgets) studies, which further demonstrted tht significnt residul CVD risk remins in ptients even fter intensive sttin therpy tht chieves LDL cholesterol gols well below 1 mg/dl It is interesting to note tht evidence suggests only modest benefits re provided by lowering LDL cholesterol from 1 to 7 mg/dl, nd some investigtors believe cogent dt supporting the use of higher sttin drug dosges nd their greter costs nd possible toxicity re limited. 13 To continue to reduce the incidence of crdiovsculr events, it is pprent tht dditionl fctors need to be ddressed. 6 Beyond LDL Cholesterol: Low HDL Cholesterol nd Elevted TGs Increse CVD Risk Residul crdiovsculr risk is likely multifctoril. Recent evidence suggests the importnt contribution to CVD risk of lipid prmeters other thn LDL cholesterol, such s high TGs nd low HDL cholesterol. 1 In n nlysis of dt from the Coronry Primry Prevention Tril, the Multiple Risk Fctor Intervention Tril, the Lipid Reserch Clinics Prevlence Mortlity Follow-up Study, nd the Frminghm Hert Study, for every 1-mg/dL (.26 mmol/l) increse in plsm HDL cholesterol in the popultions studied, there ws decrese in CHD risk of pproximtely 2% in men nd 3% in women independent of other risk fctors, including plsm LDL cholesterol. 14 According to NHANES III (Third Ntionl Helth nd Nutrition Exmintion Survey), more thn one third of the overll US dult popultion hs low HDL cholesterol. 15 Thirty-five percent of dult men nd 39% of dult women were reported to hve HDL cholesterol below 4 mg/ dl nd 5 mg/dl, respectively. 15 The NCEP ATP III (Ntionl Cholesterol Eduction Progrm Adult Tretment Pnel III) guidelines report tht low HDL cholesterol is significnt, independent risk fctor for CHD. Often, low HDL cholesterol is correlted with elevtions of serum TG nd remnnt lipoproteins, nd is strongly nd inversely ssocited with CHD risk. 16 There re number of different mechnisms through which HDL cholesterol my exert its ntitherogenic effects. The penetrtion nd retention in the rteril wll of therogenic polipoprotein B contining lipoproteins, including LDL cholesterol nd very low-density lipoprotein (VLDL) cholesterol, my initite nd promote therosclerosis. 17 A vriety of studies show HDL cholesterol my promote the efflux of cholesterol from fom cells in therosclerotic lesions through reverse cholesterol trnsport. 18 In ddition, HDL cholesterol my inhibit therogenesis through ntioxidnt nd nti-inflmmtory properties 16,18,19 nd reduce crdiovsculr events vi ntithrombotic nd vsodiltory ctivities, nd endothelil repir. 19,2 Importntly, s shown by dt from the Frminghm Hert Study, even in the presence of very low LDL cholesterol, low HDL cholesterol is still potent risk fctor. As HDL cholesterol decreses, it contributes significntly to CHD risk t ll levels of LDL cholesterol nd, even when S66 n n march 29
3 Beyond LDL Cholesterol: Low HDL Cholesterol nd Elevted TGs Increse CVD Risk LDL cholesterol levels re optiml (<1 mg/dl), the lower the HDL cholesterol level, the higher the risk of CHD. 21 Even when LDL cholesterol levels re controlled with intensive sttin therpy, the heightened risk of CHD conferred by low HDL cholesterol remins. In the TNT investigtion of high-dose sttin therpy, individuls with cceptble LDL cholesterol levels (<7 mg/dl) hd significnt, incresed 5-yer risk of CHD events tht ws directly relted to HDL cholesterol levels (Figure 2). 22 Ptients in the highest HDL cholesterol quintile (Q5 55 mg/dl) hd lower risk for mjor crdiovsculr events thn did ptients in the lowest HDL cholesterol quintile (Q1 <37 mg/ dl; hzrd rtio [HR] vs Q5,.61; 95% confidence intervl [CI], ; P =.3). 22 Although LDL cholesterol is recognized s the most importnt therogenic lipoprotein, elevtions in TG levels cn be considered mrker for therogenic VLDL remnnt lipoproteins. Becuse VLDL cholesterol is the most redily vilble mesure of therogenic remnnt lipoproteins, it my be combined with LDL cholesterol to improve CVD risk prediction s mjor components of non-hdl cholesterol. When serum TG levels re elevted, the non-hdl cholesterol mesure better represents the concentrtion of ll therogenic lipoproteins thn does LDL cholesterol. 16 Non-HDL cholesterol incorportes ll therogenic lipoproteins, including LDL cholesterol, VLDL cholesterol, lipoprotein() (Lp[]), nd intermedite-density lipoprotein (IDL) cholesterol. Non-HDL cholesterol, ccording to the NCEP ATP III guidelines, is secondry trget of therpy fter LDL cholesterol gols hve been reched nd when TG levels re 2 mg/dl. 16 A recently published met-nlysis by Srwr et l included 29 Western prospective studies (262,525 prticipnts; 1,158 CHD cses) to investigte the ssocition between TGs nd CHD risk. 23 The met-nlysis reveled n djusted odds rtio of 1.72 (95% CI, ) in ptients in the highest third of TG vlues compred with those ptients in the lowest third of TG vlues. 23 An erlier study by Genest et l reported tht in both men nd women with premture CAD, the most significnt risk fctor is low HDL cholesterol, lthough these individuls often exhibit high TG levels s well. 24 Although this study hd smll numbers of ptients with premture CAD (n = 87 men; n = 15 women), TGs were significntly higher nd HDL cholesterol ws significntly lower compred with ptients from the Frminghm Offspring Study who were free of CHD t bseline. 24 Furthermore, in the 8-yer follow-up of 4639 middle-ged men with no history of myocrdil infrction or stroke in the PROCAM (Prospective Crdiovsculr Münster) study, elevted levels of TGs emerged s significnt, independent predictor for CHD events. There ws 6-fold incresed CHD risk in ptients with TGs >2 mg/dl nd LDL cholesterol to HDL cholesterol rtio >5.. According to the PROCAM dt, high TGs put middle-ged men t incresed risk for CHD regrdless of their HDL cholesterol or LDL cholesterol levels. 25 A recent nlysis of dt from the PROVE IT-TIMI 22 tril exmined combintion of LDL cholesterol nd TG levels on CVD risk in ACS ptients. 12 During the 2-yer follow-up, significntly fewer CHD events occurred in ptients who hd LDL cholesterol <7 mg/dl thn in ptients who hd LDL cholesterol 7 mg/dl (HR,.81; P =.15). Similrly, significntly fewer events occurred n Figure 2. Low HDL-C Is Associted With High CVD Risk Even If LDL-C Levels Are Well-Controlled (TNT Study) 5-Yer Risk of Mjor CVD Events, % Q1 Q2 Q3 Q4 Q5 HDL-C Quintiles, mg/dl <37 37 to <42 42 to <47 47 to <55 >55 Hzrd Rtio vs Q In the TNT study, ptients in the highest HDL-C quintile ( 55 mg/dl) hd lower risk for mjor CVD events thn did ptients in the lowest quintile (<37 mg/dl). The men LDL-C level in this group of ptients (n = 2661, receiving sttin therpy for 3 months) ws 56 mg/dl; men TG level ws 126 mg/dl. 22 CVD indictes crdiovsculr disese; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TNT, Treting to New Trgets. P =.3 for differences mong HDL-C quintiles. This informtion ws originlly published in Brter P, et l. N Engl J Med. 27;357(13): Copyright 27 Msschusetts Medicl Society. All rights reserved. VOL. 15, No. 3 n The Americn Journl of Mnged Cre n S67
4 Report in ptients with TGs <15 mg/dl thn in those ptients with TGs 15 mg/dl, s reveled through univrite nlysis (HR,.73; 95% CI, ; P <.1). A Cox proportionl hzrds model ws utilized to further exmine the reltionship between chieved LDL cholesterol nd TGs t the dy 3 time point nd risk of recurrent CHD events. Compred with ptients who hd LDL cholesterol 7 mg/dl nd TGs 15 mg/dl, lower CHD risk ws observed with low on-tretment TGs (<15 mg/dl) nd LDL cholesterol (<7 mg/dl) (HR,.72; 95% CI, ; P =.17). 12 Ptients with TGs <15 mg/dl, even if they hd LDL cholesterol >7 mg/dl, exhibited CHD event rtes 15% lower thn those ptients who hd low LDL cholesterol but high TGs. Among ptients receiving sttin therpy fter ACS, on-tretment TGs <15 mg/dl were ssocited with lower risk of recurrent CHD events independent of the level of LDL cholesterol. Therefore, chieving both lower LDL cholesterol nd TG levels my be n importnt therpeutic strtegy in ptients with ACS. 12 When considering lipid prmeters beyond LDL cholesterol, non-hdl cholesterol (ie, totl cholesterol HDL cholesterol) is better estimte of the totl therogenic burden nd is esily clculted from nonfsting lipid vlues. Non-HDL cholesterol represents therogenic VLDL remnnt lipoproteins, including LDL cholesterol, VLDL cholesterol, IDL cholesterol, nd Lp(). 16 Dt from the Frminghm Hert Study suggest tht non-hdl cholesterol is stronger predictor of CHD risk thn is LDL cholesterol. 26 Overll, the ssocition with CHD incidence ws stronger for non-hdl cholesterol thn for LDL cholesterol t ll levels of non-hdl cholesterol, regrdless of whether TG levels were <2 or 2 mg/dl. 26 Ntionl Guideline Recommendtions for Treting Beyond LDL Cholesterol Severl ntionl guidelines ddress the tretment of high TGs nd non-hdl cholesterol nd low HDL cholesterol. Therpeutic lifestyle chnges, s noted in the NCEP ATP III recommendtions, remin very importnt nd include diet, exercise, nd smoking cesstion. The NCEP ATP III guidelines trget elevted LDL cholesterol s the primry therpeutic intervention to decrese CVD risk. 16 Becuse elevted non-hdl cholesterol levels in ptients with hypertriglyceridemi (eg, TGs 2 mg/dl) imprt incresed risk for crdiovsculr events even fter the LDL cholesterol gol hs been reched, non-hdl cholesterol is considered to be secondry therpeutic trget tht my provide dditionl CHD risk reduction. 27,28 The 24 updte to the 21 NCEP ATP III guidelines emphsized the incresing evidence for the benefits of combintion therpy, s compred with monotherpy, by recommending the possibility of dding fibrte or nicin to LDL-lowering therpy in high-risk ptients with elevted TGs or low HDL cholesterol levels. 27 In 27 the Americn Dibetes Assocition (ADA) nd the Americn Hert Assocition (AHA) collborted on joint sttement recommending LDL cholesterol remin the primry trget of lipid-modifying therpy. The ADA/AHA guidelines further recommend n LDL cholesterol gol <1 mg/dl in ptients with dibetes mellitus. 29 The ADA nd the AHA hve lso individully relesed guidelines for CVD prevention tht include therpies trgeting multiple lipid frctions. According to the 28 ADA guidelines, the primry gol in ptients with dibetes mellitus is n LDL cholesterol level <1 mg/dl in individuls without overt CVD, lthough lower LDL cholesterol gol (<7 mg/dl) is n option in individuls with overt CVD. 3 In ddition, the ADA suggests TG gol <15 mg/dl nd HDL cholesterol gols >4 mg/dl in men nd >5 mg/dl in women. 3 For ptients with TGs between 2 nd 499 mg/dl, the AHA recommends non- HDL cholesterol gol <13 mg/dl. 29 Interestingly, the AHA dvoctes efforts to rise HDL cholesterol levels but does not specificlly designte therpeutic gols. The ADA/AHA joint sttement suggests tht combintion of sttins with fibrtes or nicin my be necessry to chieve multiple lipid trgets. 29 Similr recommendtions for lipid vlues nd tretments were published in the 26 AHA/ Americn College of Crdiology Secondry Prevention Guidelines for ptients with coronry nd other therosclerotic vsculr disese. 31 This updte provides trget levels for TGs nd non-hdl cholesterol. The guidelines recommend tht if TGs re between 2 nd 499 mg/dl, the non-hdl cholesterol gol should be <13 mg/dl. Moreover, it is resonble to consider reducing non-hdl cholesterol <1 mg/dl when ptient is t sufficiently high risk for crdiovsculr events. The therpeutic S68 n n march 29
5 Beyond LDL Cholesterol: Low HDL Cholesterol nd Elevted TGs Increse CVD Risk options to reduce non-hdl cholesterol re more intensive LDL cholesterol lowering or the ddition of nicin or fibrte to reduce TGs nd increse HDL cholesterol fter LDL-lowering therpy hs been initited. 31 Combintion Therpies for Residul CVD Risk Reduction Recently, severl clinicl end point nd rteriogrphic investigtions were compred for efficcy in reducing crdiovsculr events (Figure 3). 32 Across vriety of trils, combintion therpies produced n verge clinicl event reltive risk reduction of 71.6%, n verge number needed to tret (NNT) of 9.6, nd n verge NNT per yer of These dt revel significntly enhnced efficcy for reducing clinicl events with the combintion of LDL cholesterol lowering plus HDL cholesterol rising phrmcologic therpy compred with LDL cholesterol lowering therpy lone. The SEACOAST (Sfety nd Efficcy of Fixed Dose Nicin ER nd Simvsttin Combintion Therpy) tril, 24-week rndomized clinicl tril, compred simvsttin monotherpy with combintion of extended-relese nicin (nicin ER)/ simvsttin in ptients with mixed dyslipidemi. 33,34 Following simvsttin run-in phse, during which ptients received simvsttin 2 or 4 mg for t lest 2 weeks, ptients were ssigned to either simvsttin low-dose (SEACOAST I) or simvsttin high-dose (SEACOAST II) groups. In SEACOAST I, the tretment groups were simvsttin 2 mg, nicin ER/simvsttin 1 mg/2 mg, nd nicin ER/ simvsttin 2 mg/2 mg. 34 In SEACOAST II, which included more intensive lipid-modifying therpy during both the run-in phse nd the 24-week tril phse, the tretment groups were simvsttin 8 mg, nicin ER/simvsttin 1 mg/4 mg, nd nicin ER/simvsttin 2 mg/4 mg. The primry end point in SEACOAST ws the medin percent chnge in non-hdl cholesterol during the period from bseline to week ,34 In SEACOAST I, the nicin ER/simvsttin 1 mg/2 mg nd 2 mg/2 mg combintion therpies produced significnt, dose-relted improvements in non-hdl cholesterol, HDL cholesterol, TGs, nd Lp() compred with simvsttin 2-mg monotherpy. 34 As shown in Figure 4A, 22.5% reduction in non-hdl cholesterol ws n Figure 3. Strtegies for Reducing CHD Risk Averge Clinicl Event Reltive Risk Reduction, % Clinicl Point LDL-C Trils 4S LIPID CARE WOSCOPS AFCAPS/ TexCAPS CARDS 27.2 Intensive Therpy LDL-C Trils IDEAL TNT PROVE-IT 16. Arteriogrphic LDL-C Trils MARS MAAS REGRESS PLAC-1 CCAIT 29.6 observed with high-dose nicin ER/simvsttin s compred with the 7.4% reduction seen with simvsttin 2-mg monotherpy. Although there ws dose-relted response in LDL cholesterol levels, there were no significnt differences in LDL cholesterol between these groups; simvsttin lone resulted in 7.1% decrese in LDL cholesterol, wheres high-dose nicin ER/simvsttin produced 14.2% reduction. The results of SEACOAST I lso showed 24.9% increse in HDL cholesterol ssocited with high-dose nicin ER/simvsttin nd substntil reduction in TGs tht reched 38% in the high-dose group. Finlly, significnt 25% reduction in Lp() ws observed with the high-dose nicin ER/simvsttin tretment, Arteriogrphic LDL-C Trils + HDL-C Trils FATS FATS 8-yer CLAS CLAS 2-yer HATS SCRIP 71.6 Averge NNT NNT/y In comprison of different types of trils, the LDL-C lowering plus HDL-C rising drug trils showed the gretest beneficil effects, chieving n verge clinicl event reltive risk reduction of 71.6%, n verge NNT of 9.6, nd n verge NNT/yer of AFCAPS/TexCAPS indictes Air Force/Texs Coronry Atherosclerosis Prevention Study; CARDS, Collbortive Atorvsttin Dibetes Study; CARE, Cholesterol nd Recurrent Events; CCAIT, Cndin Coronry Atherosclerosis Intervention Tril; CHD, coronry hert disese; CLAS, Cholesterol-Lowering Atherosclerosis Study; FATS, Fmilil Atherosclerosis Tretment Study; 4S, Scndinvin Simvsttin Survivl Study; HATS, HDL-Atherosclerosis Tretment Study; HDL-C, high-density lipoprotein cholesterol; IDEAL, Incrementl Decrese in Clinicl Endpoints Through Aggressive Lipid Lowering; LDL-C, low-density lipoprotein cholesterol; LIPID, Long-Term Intervention with Prvsttin in Ischemic Disese; MAAS, Multicenter Anti-Atherom Study; MARS, Monitored Atherosclerosis Regression Study; NNT, number needed to tret to prevent 1 clinicl event; PLAC-I, Prvsttin Limittion of Atherosclerosis in the Coronry Arteries; PROVE-IT, Prvsttin or Atorvsttin Evlution nd Infection Therpy; REGRESS, Regression Growth Evlution Sttin Study; SCRIP, Study of Crdiovsculr Risk Intervention by Phrmcists; TNT, Treting to New Trgets; WOSCOPS, West of Scotlnd Coronry Prevention Study. Ftl nd nonftl myocrdil infrction. VOL. 15, No. 3 n The Americn Journl of Mnged Cre n S69
6 Report n Figure 4. SEACOAST Tril of Nicin ER/Simvsttin Combintion Therpy Medin Chnge From Bseline, % b 22.5 c c Simvsttin 2 mg (n = 9) 18.3 c Nicin ER/simvsttin 1/2 mg (n = 78) Nicin ER/simvsttin 2/2 mg (n = 4) b 26.5 b 25. c 38. c Medin Bseline, mg/dl Non HDL-C LDL-C HDL-C TG Lp() A. Efficcy of nicin ER/simvsttin combintion therpy: SEACOAST I. Nicin ER/simvsttin 1-mg/2-mg nd 2-mg/2- mg combintion therpies demonstrted significnt, dose-relted improvements in non HDL-C, HDL-C, TG, nd Lp() compred with simvsttin 2-mg monotherpy. 34 ER indictes extended relese; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(), lipoprotein (); SEACOAST, Sfety nd Efficcy of Fixed Dose Nicin ER nd Simvsttin Combintion Therpy; TG, triglyceride. Simvsttin 2 mg t bseline. b P <.1 vs simvsttin 2 mg. c P <.1 vs simvsttin 2 mg. Medin Chnge From Bseline, % b 17.1 b c 21.9 c Simvsttin 8 mg (n = 9) Nicin ER/simvsttin 1/4 mg (n = 82) Nicin ER/simvsttin 2/4 mg (n = 8) d 22.8 c 21. c 31.8 c Medin Bseline, mg/dl Non HDL-C LDL-C HDL-C TG Lp() B. Efficcy of nicin ER/simvsttin combintion therpy: SEACOAST II. Nicin ER/simvsttin 1-mg/4-mg nd 2-mg/4-mg combintion therpies were comprble to simvsttin 8-mg monotherpy in reduction of non HDL-C. Both nicin ER/simv sttin 1-mg/4-mg nd 2-mg/4-mg combintion therpies resulted in significnt, dose-relted improvements in HDL-C, Lp(), nd TG compred with simvsttin 8-mg therpy. 33 ER indictes extended relese; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(), lipoprotein (); SEACOAST, Sfety nd Efficcy of Fixed Dose Nicin ER nd Simvsttin Combintion Therpy; TG, triglyceride. Simvsttin 4 mg t bseline. b Comprble to simvsttin 8 mg. c P <.1 vs simvsttin 8 mg. d P <.1 vs simvsttin 8 mg. S7 n n march 29
7 Beyond LDL Cholesterol: Low HDL Cholesterol nd Elevted TGs Increse CVD Risk wheres little chnge in Lp() ws observed with simvsttin monotherpy. A similr pttern of results ws observed in SEACOAST II, s shown in Figure 4B. A 17.1% reduction in the primry end point of non-hdl cholesterol ws seen with the high-dose nicin ER/simvsttin 2-mg/4-mg combintion therpy s compred with 1.1% reduction with simvsttin 8-mg monotherpy, lthough this difference ws not sttisticlly significnt. Decreses in LDL cholesterol were observed to be comprble ( 11.6% high-dose nicin ER/ simvsttin 2 mg/4 mg vs 12.7% simvsttin 8 mg) cross ll tretment groups. Both nicin ER/ simvsttin 1 mg/4 mg nd 2-mg/4-mg combintion therpies resulted in significnt, doserelted improvements in HDL cholesterol, Lp(), nd TGs, compred with simvsttin 8-mg therpy. 33 Across these lipid prmeters, simvsttin 8-mg monotherpy hd essentilly no effect beyond tht conferred by the simvsttin 4-mg dose dministered during the run-in phse. In SEACOAST, tretment with nicin ER/simvsttin for 24 weeks ws well-tolerted with no unnticipted dverse effects. Only flushing ws significntly more frequent with nicin ER/simvsttin combintion therpy s compred with simvsttin monotherpy, nd there ws no evidence of incresed risk of heptoxicity or myopthy with nicin ER/ simvsttin therpy. Overll, these dt support the use of nicin ER/simvsttin combintion therpy in brod popultion of dyslipidemic ptients to help them rech nd mintin multiple lipid gols. 33,34 Fibrtes, similr to nicin, hve been dded to sttin therpy to ddress multiple lipid bnormlities. Recently, new formultion of fenofibrte (fenofibric cid) hs been investigted in combintion with rosuvsttin in ptients with mixed dyslipidemi. This 12-week, rndomized, double-blind, ctive-controlled tril compred the efficcy of fenofibric cid 135-mg monotherpy, rosuvsttin 1-mg monotherpy, nd fenofibric cid/rosuvsttin 135-mg/1-mg combintion therpy in ptients with mixed dyslipidemi. Combintion therpy with fenofibric cid/rosuvsttin (Figure 5) resulted in significntly greter reduction in LDL cholesterol compred with fenofibric cid monotherpy n Figure 5. Fenofibric Acid nd Rosuvsttin Combintion Therpy in Ptients With Mixed Dyslipidemi Men % Chnge From Bseline Fenofibric cid 135 mg 2.3 c Rosuvsttin 1 mg 15. Fenofibric cid/rosuvsttin 135/1 mg 8.5 n = 223 n = 243 n = 231 n = 242 n = 252 n = 252 n = 22 n = 239 n = b 47.1 c Medin Bseline, mg/dl LDL-C HDL-C TG Combintion therpy with fenofibric cid nd rosuvsttin resulted in significntly greter reduction in LDL-C compred with fenofibric cid monotherpy. Combintion therpy with fenofibric cid nd rosuvsttin lso resulted in significntly greter increses in HDL-C nd reductions in TGs compred with rosuvsttin monotherpy. 35 HDL-C indictes high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride. Mixed dyslipidemi: LDL-C 13 mg/dl, TG 15 mg/dl, nd HDL-C <4 mg/dl in men nd <5 mg/dl in women. b P <.1 vs fenofibric cid. c P <.1 vs rosuvsttin 1 mg. VOL. 15, No. 3 n The Americn Journl of Mnged Cre n S71
8 Report (P <.1). Combintion therpy with fenofibric cid/rosuvsttin resulted in significntly greter increses in HDL cholesterol nd reductions in TGs compred with rosuvsttin 1-mg monotherpy (P <.1). 35 In ddition to its beneficil effects on vrious lipid prmeters, fenofibric cid/rosuvsttin combintion therpy resulted in substntil shift in the percentge of ptients with lrge, less therogenic LDL prticles from 13.3% t bseline to 51.8% following 12 weeks of therpy. Conversely, rosuvsttin monotherpy produced more modest shift, with only 18.2% of ptients expressing lrge, less therogenic LDL prticles s compred with 6.8% t bseline. 36 Fenofibric cid/rosuvsttin combintion therpy lso resulted in significntly greter improvements in the rtios of totl cholesterol to HDL cholesterol, non-hdl cholesterol to HDL cholesterol, polipoprotein B to polipoprotein A-I, nd TG to HDL cholesterol compred with fenofibric cid monotherpy or rosuvsttin monotherpy. 37 Importntly, fenofibric cid/rosuvsttin combintion therpy ws well-tolerted; no heptic, renl, or muscle sfety signls were identified. 35 Summry Severl lipid prmeters, such s LDL cholesterol, TGs, HDL cholesterol, nd therogenic remnnt lipoproteins, re strongly ssocited with therosclerosis nd heightened CVD risk. The primry therpeutic trget is LDL cholesterol, nd lipid-lowering therpy with sttins hs proved to be highly beneficil for reducing crdiovsculr event rtes. However, significnt crdiovsculr risk remins in ptients treted even with intensive sttin therpy to reduce LDL cholesterol. As result, there hs been n incresed focus on elevted TGs nd low HDL cholesterol nd their significnt contributions to crdiovsculr risk even when LDL cholesterol levels re well-controlled. Tretment guidelines recommend tht combintion therpy my be necessry to chieve multiple lipid gols, including non-hdl cholesterol, HDL cholesterol, nd TGs. When considering ll of the evidence ddressing vrious lipid frctions nd CVD risk, lipid mngement in specific ptients should not be limited to sttin monotherpy. Rther, chieving multiple lipid gols nd reducing CVD risk should utilize sttins nd dditionl therpeutic gents to trget lipid prmeters other thn LDL cholesterol when necessry. The benefits conferred by rising HDL cholesterol with nicin pper dditive to LDL cholesterol lowering with sttins. This combintion ddresses severl therogenic lipid bnormlities, slows the progression of therosclerosis, nd reduces residul CVD risk. Nicin/sttin combintion therpy hs n excellent sfety profile nd my be needed to optimlly reduce CVD risk in high-risk ptients. Similrly, recent reports indicte tht combintion therpy of fenofibric cid with rosuvsttin lso ppers to sfely nd effectively correct severl therogenic lipid bnormlities. Consequently, severl options exist for combintion lipid therpy tht my be necessry to optimlly ddress multiple lipid bnormlities nd improve ptient outcomes. Author Affilition: From Pennsylvni Stte College of Medicine, Penn Stte Hert nd Vsculr Institute, Hershey, PA. Funding Source: This work ws supported by n eductionl grnt from Solvy Phrmceuticls nd Abbott. Author Disclosure: Honorri: Abbott, Merck Schering- Plough, Pfizer. Authorship Informtion: Concept nd design; drfting of the mnuscript; criticl revision of the mnuscript for importnt intellectul content; supervision. Address correspondence to: Peter Algon Jr, MD, FACC, The Milton S. Hershey Medicl Center, Pennsylvni Stte Hert nd Vsculr Institute, H47, 5 University Dr, Hershey, PA E-mil: plgon@hmc.psu.edu. References 1. Fruchrt JC, Scks FM, Hermns MP, et l. The Residul Risk Reduction Inititive: cll to ction to reduce residul vsculr risk in ptients with dyslipidemi. Am J Crdiol. 28;12(suppl):1K-34K. 2. Ghndehri H, Kml-Bhl S, Wong ND. Prevlence nd extent of dyslipidemi nd recommended lipid levels in US dults with nd without crdiovsculr comorbidities: the Ntionl Helth nd Nutrition Exmintion Survey Am Hert J. 28;156(1): Rndomised tril of cholesterol lowering in 4444 ptients with coronry hert disese: the Scndinvin Simvsttin Survivl Study (4S). Lncet. 1994;344(8934): Prevention of crdiovsculr events nd deth with prvsttin in ptients with coronry hert disese nd brod rnge of initil cholesterol levels. The Long-Term Intervention with Prvsttin in Ischemic Disese (LIPID) Study Group. N Engl J Med. 1998;339(19): Hert Protection Study Collbortive Group. MRC/ BHF Hert Protection Study of cholesterol lowering with simvsttin in 2,536 high-risk individuls: rndomised plcebo-controlled tril. Lncet. 22;36(9326):7-22. S72 n n march 29
9 Beyond LDL Cholesterol: Low HDL Cholesterol nd Elevted TGs Increse CVD Risk 6. Downs JR, Clerfield M, Weis S, et l. Primry prevention of cute coronry events with lovsttin in men nd women with verge cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texs Coronry Atherosclerosis Prevention Study. JAMA. 1998;279(2): Scks FM, Pfeffer MA, Moye LA, et l. The effect of prvsttin on coronry events fter myocrdil infrction in ptients with verge cholesterol levels. Cholesterol nd Recurrent Events Tril investigtors. N Engl J Med. 1996;335(14): Shepherd J, Cobbe SM, Ford I, et l. Prevention of coronry hert disese with prvsttin in men with hypercholesterolemi. West of Scotlnd Coronry Prevention Study Group. N Engl J Med. 1995;333(2): Cnnon CP, Brunwld E, McCbe CH, et l. Intensive versus moderte lipid lowering with sttins fter cute coronry syndromes. N Engl J Med. 24;35(15): LRos JC, Grundy SM, Wters DD, et l. Intensive lipid lowering with torvsttin in ptients with stble coronry disese. N Engl J Med. 25;352(14): Pedersen TR, Fergemn O, Kstelein JJ, et l. High-dose torvsttin vs usul-dose simvsttin for secondry prevention fter myocrdil infrction: the IDEAL study: rndomized controlled tril. JAMA. 25;294(19): Miller M, Cnnon CP, Murphy SA, Qin J, Ry KK, Brunwld E. Impct of triglyceride levels beyond lowdensity lipoprotein cholesterol fter cute coronry syndrome in the PROVE IT-TIMI 22 tril. J Am Coll Crdiol. 28;51(7): Hywrd RA, Hofer TP, Vijn S. Nrrtive review: lck of evidence for recommended low-density lipoprotein tretment trgets: solvble problem. Ann Intern Med. 26;145(7): Gordon DJ, Probstfield JL, Grrison RJ, et l. Highdensity lipoprotein cholesterol nd crdiovsculr disese. Four prospective Americn studies. Circultion. 1989;79(1): Ford ES, Giles WH, Dietz WH. Prevlence of the metbolic syndrome mong US dults: findings from the third Ntionl Helth nd Nutrition Exmintion Survey. JAMA. 22;287(3): Third Report of the Ntionl Cholesterol Eduction Progrm (NCEP) Expert Pnel on Detection, Evlution, nd Tretment of High Blood Cholesterol in Adults (Adult Tretment Pnel III) finl report. Circultion. 22;16(25): Tbs I, Willims KJ, Boren J. Subendothelil lipoprotein retention s the inititing process in therosclerosis: updte nd therpeutic implictions. Circultion. 27;116(16): Berliner JA, Nvb M, Fogelmn AM, et l. Atherosclerosis: bsic mechnisms. Oxidtion, inflmmtion, nd genetics. Circultion. 1995;91(9): Assmnn G, Nofer JR. Atheroprotective effects of highdensity lipoproteins. Annu Rev Med. 23;54: Chpmn MJ, Assmnn G, Fruchrt JC, Shepherd J, Sirtori C. Rising high-density lipoprotein cholesterol with reduction of crdiovsculr risk: the role of nicotinic cid position pper developed by the Europen Consensus Pnel on HDL-C. Curr Med Res Opin. 24;2(8): Cstelli WP. Cholesterol nd lipids in the risk of coronry rtery disese the Frminghm Hert Study. Cn J Crdiol. 1988;4(suppl A):5A-1A. 22. Brter P, Gotto AM, LRos JC, et l. HDL cholesterol, very low levels of LDL cholesterol, nd crdiovsculr events. N Engl J Med. 27;357(13): Srwr N, Dnesh J, Eiriksdottir G, et l. Triglycerides nd the risk of coronry hert disese: incident cses mong prticipnts in 29 western prospective studies. Circultion. 27;115(4): Genest JJ Jr, Mrtin-Munley SS, McNmr JR, et l. Fmilil lipoprotein disorders in ptients with premture coronry rtery disese. Circultion. 1992;85(6): Assmnn G, Schulte H, von Eckrdstein A. Hypertriglyceridemi nd elevted lipoprotein() re risk fctors for mjor coronry events in middle-ged men. Am J Crdiol. 1996;77(14): Liu J, Sempos CT, Donhue RP, Dorn J, Trevisn M, Grundy SM. Non-high-density lipoprotein nd very-lowdensity lipoprotein cholesterol nd their risk predictive vlues in coronry hert disese. Am J Crdiol. 26;98(1): Grundy SM, Cleemn JI, Merz CN, et l. Implictions of recent clinicl trils for the Ntionl Cholesterol Eduction Progrm Adult Tretment Pnel III guidelines. Circultion. 24;11(2): Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, nd polipoprotein B s trgets of lipid-lowering therpy. Circultion. 22;16(2): Buse JB, Ginsberg HN, Bkris GL, et l. Primry prevention of crdiovsculr diseses in people with dibetes mellitus: scientific sttement from the Americn Hert Assocition nd the Americn Dibetes Assocition. Dibetes Cre. 27;3(1): Americn Dibetes Assocition. Stndrds of medicl cre in dibetes 28. Dibetes Cre. 28;31(suppl 1): S12-S Smith SC Jr, Allen J, Blir SN, et l. AHA/ACC guidelines for secondry prevention for ptients with coronry nd other therosclerotic vsculr disese: 26 updte: endorsed by the Ntionl Hert, Lung, nd Blood Institute. Circultion. 26;113(19): Superko HR, King S 3rd. Lipid mngement to reduce crdiovsculr risk: new strtegy is required. Circultion. 28;117(4): Bllntyne CM, Dvidson MH, McKenney J, Keller LH, Bjoruns DR, Krs RH. Comprison of the efficcy nd sfety of combintion tblet of nicin extendedrelese nd simvsttin with simvsttin 8 mg monotherpy: the SEACOAST II (high-dose) study. J Clin Lipidol. 28;2: Bllntyne CM, Dvidson MH, McKenney J, Keller LH, Bjoruns DR, Krs RH. Comprison of the sfety nd efficcy of combintion tblet of nicin extended relese nd simvsttin vs simvsttin monotherpy in ptients with incresed non-hdl cholesterol (from the SEACOAST I study). Am J Crdiol. 28;11(1): Jones PH, Buttler SM, Dvidson MH, et l. Efficcy nd sfety of ABT-335 (fenofibric cid) in combintion with rosuvsttin in ptients with mixed dyslipidemi: phse 3 study. J Clin Lipidol. 28;2(3): Jones PH, Crlson DM, Dyspring T, et l. Effects of ABT-335 in combintion with rosuvsttin on lowdensity lipoprotein prticle size in ptients with mixed dyslipidemi. J Clin Lipidol. 28;2(3): Dvidson MH, Crlson DM, Guthrie RM, et l. ABT-335 in combintion with rosuvsttin improves multiple lipid rtios in ptients with mixed dyslipidemi. J Clin Lipidol. 28;2(3): VOL. 15, No. 3 n The Americn Journl of Mnged Cre n S73
PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationTrends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
ORIGINAL ARTICLE Trends in ntihypertensive nd lipidlowering therpy in subjects with type II dibetes: clinicl effectiveness or clinicl discretion? MC Gulliford, J Chrlton nd R Ltinovic Deprtment of Public
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationEffect on Glycemic, Blood Pressure, and Lipid Control according to Education Types
Originl Article http://dx.doi.org/10.4093/dmj.2011.35.6.580 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L Effect on Glycemic, Blood Pressure, nd Lipid Control ccording
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationLipid-Lowering Agents
Lipid-Lowering Agents Edwrd JN Ishc, Ph.D. Smith Building, Room 742 eishc@vcu.edu 828-2127 Deprtment of Phrmcology nd Toxicology Medicl College of Virgini Cmpus of Virgini Commonwelth University Richmond,
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationEVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1
Swine Dy 2001 Contents EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 C. W. Hstd, S. S. Dritz 2, J. L. Nelssen, M. D. Tokch, nd R. D. Goodbnd Summry Two trils were
More informationReport of the Conference on Low Blood
1046 Report of the Conference on Low Blood Cholesterol: Mortlity Associtions Dvid Jcobs, PhD; Henry Blckburn, MD; Millicent Higgins, MD; Dwyne Reed, MD, PhD; Hiroysu Iso, MD; Grdner McMilln, MD, PhD; Jmes
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationStudy of the Use of Lipid Panels as a Marker of Insulin Resistance to Determine Cardiovascular Risk
credits vilble for this rticle see pge 96. Study of the Use of Lipid Pnels s Mrker of Insulin Resistnce to Determine Crdiovsculr Risk Ruth Ann Bertsch, MD, PhD, FACP; Mqdood A Merchnt, MSc, MA ABSTRACT
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationBMI and Mortality: Results From a National Longitudinal Study of Canadian Adults
nture publishing group BMI nd Mortlity: Results From Ntionl Longitudinl Study of Cndin Adults Hether M. Orpn 1, Jen-Mrie Berthelot 2,3, Mrk S. Kpln 4, Dvid H. Feeny 5,6, Bentson McFrlnd 7 nd Nncy A. Ross
More informationDiabetes affects 29 million Americans, imposing a substantial
CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.
More informationThe Association of Gender With Quality of Health in Peripheral Arterial Disease Following Peripheral Vascular Intervention
The Assocition of Gender With Qulity of Helth in Peripherl Arteril Disese Following Peripherl Vsculr Intervention Sudrshn Pudel, MD 1 ; Anwr Zitoun, MD 1 ; Sif Al-Njfi, MD 2 ; Ther Mus, MD 3 ; Susn Szpunr,
More informationEFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE
Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationMetabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction
Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson
More informationTHE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS
THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS John F. Ptience nd Doug Gillis SUMMARY
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationThe Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes
Originl Article doi: 10.4093/kdj.2010.34.3.166 pissn 1976-9180 eissn 2093-2650 The Effects of Smll Sized Rice Bowl on Crbohydrte Intke nd Dietry Ptterns in Women with Type 2 Dibetes Hee-Jung Ahn 1, *,
More informationT.S. Kurki a, *,U.Häkkinen b, J. Lauharanta c,j.rämö d, M. Leijala c
Europen Journl of Crdio-thorcic Surgery 20 (2001) 1183 1187 www.elsevier.com/locte/ejcts Evlution of the reltionship between preopertive risk scores, postopertive nd totl length of stys nd hospitl costs
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationSerum γ-glutamyltransferase: Independent Predictor of Risk of Diabetes, Hypertension, Metabolic Syndrome, and Coronary Disease
nture publishing group Serum γ-glutmyltrnsferse: Independent Predictor of Risk of Dibetes, Hypertension, Metbolic Syndrome, nd Coronry Disese Altn Ont 1, Güny Cn 2, Ender Örnek 3, Gökhn Çiçek 4, Erkn Ayhn
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationSystematic review of the impact of beta blockers on mortality and hospital admissions in heart failure
Ž. Europen Journl of Hert Filure 3 2001 351 357 Systemtic review of the impct of bet blockers on mortlity nd hospitl dmissions in hert filure Mrcelo C. Shibt,, Mrcus D. Flther,b, Duolo Wng c Clinicl Trils
More informationRefining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
CHEST Originl Reserch Refining Clinicl Risk Strtifiction for Predicting Stroke nd Thromboembolism in Atril Fibrilltion Using Novel Risk Fctor-Bsed Approch The Euro Hert Survey on Atril Fibrilltion THROMBOEMBOLISM
More informationOriginal Article. Diabetes Metab J 2011;35:26-33 doi: /dmj pissn eissn
Originl Article Dibetes Metb J 211;35:26-33 doi: 1.493/dmj.211.35.1.26 pissn 2233-679 eissn 2233-687 D I A B E T E S & M E T A B O L I S M J O U R N A L Comprison of the Efficcy of Glimepiride, Metformin,
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationVariability in lipid profile among patients presented with acute myocardial infarction, unstable angina and stable angina pectoris
Europen Review for Medicl nd Phrmcologicl Sciences 2014; 18: 3761-3766 Vribility in lipid profile mong ptients presented with cute myocrdil infrction, unstble ngin nd stble ngin pectoris N. YANG, J.-P.
More informationAssessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II
Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationFat intake in patients newly diagnosed with type 2 diabetes: a 4-year follow-up study in general practice
Originl ppers Ft intke in ptients newly dignosed with type 2 dibetes: 4-yer follow-up study in generl prctice Floris A vn de Lr, Eloy H vn de Lisdonk, Peter L B J Lucssen, J M H Tigchelr, Sski Meyboom,
More informationImpact of left ventricular hypertrophy on survival in end-stage renal disease
Kidney Interntionl, Vol. 36 (1989), pp. 286 290 Impct of left ventriculr hypertrophy on survivl in end-stge renl disese JONATHAN S. SILBERBERG, PAUL E. BARRE, SARAH S. PRICHARD, nd ALLAN D. SNIDERMAN Divisions
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationMecadox. Improves pig performance in a wide range of health and growing conditions. (Carbadox) Talk With a Phibro Expert:
SWINE (Crbdox) Improves pig performnce in wide rnge of helth nd growing conditions The Advntge Over the yers, medicted feed dditive hs proven to be cost-effective mngement tool for improving pig performnce
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationWSU Tree Fruit Research and Extension Center, Wenatchee (509) ext. 265;
FINAL REPORT WTFRC Project # AH-1-5 WSU Project # 13C-355-3 Project title: PI: Orgniztion: Coopertors: of Sunburn in Apples with RAYNOX Lrry Schrder, Horticulturist WSU Tree Fruit Reserch nd Extension
More informationEstimated Prevalence and Economic Burden of Severe, Uncontrolled Asthma in the United States
Estimted Prevlence nd Economic Burden of Severe, Uncontrolled Asthm in the United Sttes Cheryl S. Hnkin 1 ; Amy Bronstone 1 ; Zhohui Wng 1 ; Mry Butti-Smll 2 ; Philip O. Buck 2 1 BioMedEcon, Moss Bech,
More informationDivision of Endocrinology and Metabolism, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, 2
Originl Article Epidemiology http://dx.doi.org/1.493/dmj.214.38.1.51 pissn 2233-679 eissn 2233-687 DIABETES & METABOLISM JOURNAL Higher Prevlence nd Awreness, but Lower Control Rte of Hypertension in Ptients
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationManagement and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence
Clinicin Summry Mentl Helth Eting Disorders Mngement nd Outcomes of Binge-Eting Disorder in Adults: Current Stte of the Evidence Focus of This Summry This is summry of systemtic review evluting the evidence
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationDo Statins Reduce Atrial Fibrillation After Coronary Artery Bypass Grafting?
Do Sttins Reduce Atril Fibrilltion After Coronry Artery Bypss Grfting? Anil Pturi, MD, Amn Shukl, MD b, George Ebr, Ed.D c, Viet Nguyen, DO d, Steven Borzk, MD e Myo Clinic, Rochester, Minnesot, USA. b
More informationPROVEN ANTICOCCIDIAL IN NEW FORMULATION
PROVEN ANTICOCCIDIAL IN NEW FORMULATION Coxidin 100 microgrnulte A coccidiosttic dditive for roilers, chickens rered for lying nd turkeys Contins 100 g of monensin sodium per kg Aville s homogenous grnules
More informationDietary Sodium Intake in People with Diabetes in Korea: The Korean National Health and Nutrition Examination Survey for 2008 to 2010
Originl Article Epidemiology Dietes Met J 2016;40:290-296 http://dx.doi.org/10.4093/dmj.2016.40.4.290 pissn 2233-6079 eissn 2233-6087 DIABETES & METABOLISM JOURNAL Dietry Sodium Intke in People with Dietes
More informationBudesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
Journl of Crohn's nd Colitis, 2017, 785 791 doi:10.1093/ecco-jcc/jjx032 Advnce Access publiction Mrch 4, 2017 Originl Article Originl Article Budesonide Multimtrix Is Efficcious for Meslmine-refrctory,
More informationSummary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV)
Summry Effect evlution of the Rehbilittion of Drug-Addicted Offenders Act (SOV) The Rehbilittion of Drug-Addicted Offenders Act (SOV) ws lunched on April first 2001. This lw permitted the compulsory plcement
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationA cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis
Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu
More informationOriginal Article INTRODUCTION. Korean Diabetes J 2010;34: doi: /kdj pissn eissn
Originl Article doi: 1.493/kdj.21.34.6.34 pissn 1976-918 eissn 293-265 The Smll Rice Bowl-Bsed Mel Pln ws Effective t Reducing Dietry Energy Intke, Body Weight, nd Blood Glucose Levels in Koren Women with
More informationThe Quality and Outcomes Framework (QOF) is a pay-for-performance
Effect of UK Py-for-Performnce Progrm on Ethnic Disprities in Dibetes Outcomes: Interrupted Time Series Anlysis Riydh Alshmsn, MSc John Tyu Lee, MSc Azeem Mjeed, MD Goplkrishnn Netuveli, PhD Christopher
More informationEstimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain
Rpid communictions Estimting the impct of the influenz pndemic on mortlity in the elderly in Nvrre, Spin J Cstill (jcstilc@nvrr.es) 1, J Etxeberri 1, E Ardnz 1, Y Floristán 1, R López Escudero 1, M Guevr
More informationThe Acute Time Course of Concurrent Activation Potentiation
Mrquette University e-publictions@mrquette Exercise Science Fculty Reserch nd Publictions Exercise Science, Deprtment of 1-1-2010 The Acute Time Course of Concurrent Activtion Potentition Luke Grceu Mrquette
More informationBariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI,35 kg/m 2
924 Dibetes Cre Volume 39, June 2016 METABOLIC SURGERY Britric/Metbolic Surgery to Tret Type 2 Dibetes in Ptients With BMI,35 kg/m 2 Dibetes Cre 2016;39:924 933 DOI: 10.2337/dc16-0350 Dvid E. Cummings
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationRed cell distribution width and risk of peripheral artery disease: Analysis of National Health and Nutrition Examination Survey
442443VMJ17310.1177/1358863X12442443Zlwdiy SK et l.vsculr Medicine 2012 Red cell distribution width nd risk of peripherl rtery disese: Anlysis of Ntionl Helth nd Nutrition Exmintion Survey 1999 2004 Vsculr
More informationA series of recent studies and meta-analyses confirm
Originl Reserch Clinicl Medicine & Reserch Volume 11, Number 4: 210-218 2013 Mrshfield Clinic clinmedres.org Brest nd Prostte Cncer Survivors in Dibetic Cohort: Results from the Living With Dibetes Study
More informationEthnic Disparities in Stroke Recognition in Individuals with Prior Stroke
Reserch Articles Ethnic Disprities in Stroke Recognition in Individuls with Prior Stroke Chrles Ellis, PhD Leonrd E. Egede, MD, MS,c SYNOPSIS Ojective. Studies of stroke wreness suggest tht knowledge of
More informationThe potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens
The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic
More informationNonpharmacologic Interventions for Treatment-Resistant Depression in Adults Executive Summary
Comprtive Effectiveness Review Numer 33 Effective Helth Cre Progrm Nonphrmcologic Interventions for Tretment-Resistnt Depression in Adults Executive Summry Bckground Mjor depressive disorder (MDD) is common
More informationSoybean Hulls as an Alternative Feed for Horses
Animl Industry Report AS 650 ASL R1931 2004 Soyben Hulls s n Alterntive Feed for Horses Josie Booth Iow Stte University Howrd Tyler Iow Stte University Peggy Miller-Auwerd Iow Stte University Jenette Moore
More informationRegression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study
(2004) 18, 403 409 & 2004 Nture Pulishing Group All rights reserved 0950-9240/04 $30.00 www.nture.com/jhh ORIGINAL ARTICLE Regression of electrocrdiogrphic left ventriculr hypertrophy predicts regression
More informationAge related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer
MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationProposed Project Plan
Proposed Project Pln Comprison of triple conventionl synthetic disese-modifying ntirheumtic drugs nd biologic drugs or Jnus-ssocited kinse inhibitors for rheumtoid rthritis 28November 2018 BACKGROUND AND
More informationMetabolic syndrome (MetS) is defined by a group
ORIGINAL ARTICLE Prevlence of Metolic Syndrome in Lrge Integrted Helth Cre System in North Crolin Rohn Mhleshwrkr, Yhenneko J. Tylor, Melnie D. Spencer, Svet Mohnn ckground Metolic syndrome (MetS) is cluster
More informationThiazolidinediones: A 2010 Perspective
credits vilble for this rticle see pge 95. Thizolidinediones: A 2010 Perspective Ashok Krishnswmi, MD, FACC Shlini Rvi-Kumr, MD John M Lewis, MD Abstrct A lrge number of crdiology clinicl trils hve mortlity
More informationBody mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health
Originl Article - Sexul Dysfunction/Infertility pissn 2005-6737 eissn 2005-6745 Body mss index, wist-to-hip rtio, nd metbolic syndrome s predictors of middle-ged men's helth Jung Hyun Prk *, In-Chng Cho
More informationAssociations of Psoriatic Arthritis and Cardiovascular Conditions in a Large Population
ville online: www.kp.org/permnentejournl Originl rticle Associtions of Psoritic Arthritis nd Crdiovsculr Conditions in Lrge Popultion Svetln Kondrtiouk, DO Ntli Udltsov, PhD Arthur L Kltsky, MD Astrct
More informationOriginal Investigation. management of type 2 diabetes mellitus.
Reserch Originl Investigtion Roux-en-Y Gstric Bypss Surgery or Lifestyle With Intensive Medicl Mngement in Ptients With Type 2 Dibetes Fesibility nd 1-Yer Results of Rndomized Clinicl Tril Florenci Hlperin,
More informationClinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population
Originl Article Clinicl sttistics nlysis on the chrcteristics of pneumoconiosis of Chinese miner popultion Mei-Fng Wng 1 *, Run-Ze Li 2 *, Ying Li 2, Xue-Qin Cheng 1, Jun Yng 1, Wen Chen 3, Xing-Xing Fn
More informationCheckMate-142 Study Design
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Thierry André, 1 Sr
More informationEffect of supplemental fat from dried distillers grains with solubles or corn oil on cow performance, IGF-1, GH, and NEFA concentrations 1
Effect of supplementl ft from dried distillers grins with solules or corn oil on cow performnce, IGF-1, GH, nd NEFA concentrtions 1 Aigil Brtosh 2, Cody Wright 3, Aimee Wertz-Lutz 4, nd George Perry 5
More informationResearch Article Cholesterol Metabolism and Weight Reduction in Subjects with Mild Obstructive Sleep Apnoea: A Randomised, Controlled Study
Cholesterol Volume 2013, Article ID 769457, 9 pges http://dx.doi.org/10.1155/2013/769457 Reserch Article Cholesterol Metbolism nd Weight Reduction in Subjects with Mild Obstructive Sleep Apnoe: A Rndomised,
More informationkey words: chronic obstructive pulmonary disease, beta agonists, Medicare, health care costs, health care utilization
reserch report Helth Cre Use nd Costs Among Medicre Ptients With Chronic Obstructive Pulmonry Disese Treted With Short-Acting Bet Agonists or Long-Acting Bet Agonists Flvi Ejzykowicz, PhD; 1 Vmsi K Bollu,
More informationPerioperative beta-blockers in noncardiac surgery: The evidence continues to evolve
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Reders will weigh the evidence for nd ginst the periopertive use of bet-blockers MUZAMMIL MUSHTAQ, MD Assistnt Professor of Clinicl Medicine, Interdisciplinry Stem
More informationT max (hr) 1.5 ± ± ± 0.6 AUC (0-10) (ng hr/ml)
Progesterone Cpsules (progesterone, USP), 100 mg nd 200 mg WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER nd PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Crdiovsculr Disorders nd Probble Dementi
More informationInhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD
CHEST Originl Reserch Inhled Corticosteroid Is Associted With n Incresed Risk of TB in Ptients With COPD Jung-Hyun Kim, MD ; Ji-Soo Prk, MD ; Kyung-Ho Kim, MD ; Hye-Cheol Jeong, MD ; Eun-Kyung Kim, MD
More informationAnalysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia
284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More information10-15 mg/day 15 mg/day 30 mg/day. 2-5 mg/day 5-10 mg/day 15 mg/day. 2 mg/day 5-10 mg/day 15 mg/day. 30 mg/day injected IM
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ABILIFY sfely nd effectively. See full prescribing informtion for ABILIFY. Tblets ABILIFY DISCMELT
More informationTherapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia
originl rticle The Americn Society of Gene Therpy see pge 808 Therpeutic Angiogenesis With Intrmusculr NV1FGF Improves Amputtion-free Survivl in Ptients With Criticl Limb Ischemi Sigrid Nikol 1, Iris Bumgrtner
More information